Genprex, Inc.
GNPXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The $2.9M market capitalization puts GNPX squarely in micro-cap range for its industry. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Market Cap
$2.9M
Beta
-0.93
P/E (TTM)
0.10
P/E (Fwd)
-1.62
EPS (TTM)
$34.43
EPS (Fwd)
$-2.18
ROE
-203.9%
ROA
-94.5%
Cash
$15.2M
Total Debt
$0
Free CF
-$10.6M
52W Change
-98.7%
Annual Financials
Cash vs Debt
Where GNPX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GNPX finished 84.64% below its 150-day moving average ($22.85) and 88.95% below its 200-day moving average ($31.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GNPX overbought or oversold?
At the September 3, 2026 close, GNPX's RSI(14) was 17.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Genprex, Inc. reports $15.2M in cash and $0 in total debt. Free cash flow is running at -$10.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -203.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Genprex, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing GNPX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.